{
  "docId": "019de073-cd7d-722a-8136-5a45a3cc0efe",
  "docSlug": "303c45082bb692ab214f73eda43168dc",
  "documentTitle": "NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides",
  "authorId": "neurobo-pharmaceuticals",
  "authorName": "NeuroBo Pharmaceuticals",
  "documentKindSlug": "regulatory-filing",
  "documentKindLabel": "Regulatory filing",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 30,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 16,
  "notes": "Study design timeline included; statistical significance noted for treatment groups.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-cd7d-722a-8136-5a45a3cc0efe/11",
  "deckHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe",
  "deckJsonHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe.json",
  "deckAnchorHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.22,
        "x": 0.05,
        "y": 0.6
      },
      "kind": "chart",
      "text": "NAFLD Activity Score",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5c9866e0-6d82-4781-a13c-b9ea4ea9add6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.22,
        "x": 0.74,
        "y": 0.6
      },
      "kind": "chart",
      "text": "Total Liver Galectin-3 (mg)",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "70cc43e1-ba49-433f-8237-d11e0bc3a5fa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.22,
        "x": 0.51,
        "y": 0.6
      },
      "kind": "chart",
      "text": "Total Liver Lipid (mg)",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8ca22ade-d731-4144-a51a-7f0217f14ebc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.22,
        "x": 0.28,
        "y": 0.6
      },
      "kind": "chart",
      "text": "Inflammation Score",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b050ce63-3e26-49c9-9cc0-85e510c441f6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.38,
        "x": 0.58,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "Study timeline showing 27 weeks of Western diet followed by 8 weeks of treatment.",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5f5a1f18-b735-4dd0-9688-1b986b215507",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.55,
        "x": 0.05,
        "y": 0.22
      },
      "kind": "list",
      "text": "The beneficial effects of DA-1241 alone and in combination with a DPP4 inhibitor were carried over to NASH models in mice. DA-1241 alone and in combination with a DPP4 inhibitor reduced hepatic lipid and collagen deposition in the liver of biopsy-proven NASH mice. DA-1241 alone and in combination with a DPP4 inhibitor effectively decreased hepatic inflammation assessed by a macrophage marker, galectin-3. DA-1241 alone and in combination with a DPP4 inhibitor reduced systemic inflammation and fibrosis biomarkers.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "de9f4c9a-ed67-4671-b20e-5a523d54075f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.5,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "NASH (Non-Alcoholic Steatohepatitis); NAFLD (Non-Alcoholic Fatty Liver Disease); DIO (Diet Induced Obese); DPP4i (Dipeptidyl Peptidase 4). Dong-A Study Report 103420. Park H et al. AASLD The Liver Meeting. 2020; Abstract 1666. Park H et al. 80th Meeting of the American Diabetes Association. 2020; Abstract 216-LB.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "62eb2e98-ca32-429e-9e89-129325cc0dd5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.05,
        "y": 0.04
      },
      "kind": "title",
      "text": "Therapeutic Potential of DA-1241 in Diet Induced Obesity -NASH Mice (1-3)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4e9ffdab-409c-44ce-8b05-1c81596d93c3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Waterfall chart",
      "slug": "waterfall-chart",
      "agent": null,
      "layer": "slide",
      "matchId": "1d5b4a0c-bf35-4eba-b03e-69c11c265727",
      "evidence": "chart/waterfall: Waterfall plot of best % change in target lesions",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 8,
      "beatId": "62b08f58-f4f0-41db-851b-8bca195351b7",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The document presents DA-1241 and DA-1726 as potential solutions",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    },
    {
      "to": 20,
      "from": 9,
      "beatId": "c197e3f3-07b5-49d1-aab7-fa59606c4a1f",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Product",
      "beatSlug": "sequoia-pitch-product",
      "evidence": "The document presents the mechanism of action and therapeutic potential of DA-1241 and DA-1726",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 8,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "566d6fa7-b9ed-43cf-a2b7-eea26c41398d",
      "evidence": "The document presents DA-1241 and DA-1726 as potential solutions with therapeutic potential",
      "position": 1,
      "objective": "Can DA-1241 and DA-1726 provide a quick win or a big bet for investors?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}